



Innovation Through Collaboration
National Cancer Institute
Technology Transfer Center
National Institutes of Health



NCI START-UP 3.0: AN EVALUATION OPTION LICENSE PROGRAM



Provides short-term exclusivity to certain National Cancer Institute technologies while companies:

- evaluate a technology, and/or
- raise funds for its future development

Available to Companies Meeting These Criteria:

- Less than 7 years old
- Less than \$15M capital raised (exclusive of non-dilutive grant funding)
- Majority owned by individuals or by company majority owned by individuals

Features Include:

- 24-month initial license term; evaluation phase
- \$5,000 execution royalty within 60 days of the effective date
- Cost sharing of ongoing patent expenses with an opportunity to consult on matters of patent filing and prosecution
- Option to extend license term through life of the patent rights



Therapeutics



Diagnostics



Research Tools



Vaccines



Devices



Software

Process to Obtain a Start-Up Evaluation Option License:

1. Identify a technology of interest from the list of NCI inventions below:
 - List: <https://techtransfer.cancer.gov/available-technologies>
2. Confirm with the Technology Transfer Manager (TTM) supporting the technology that it is suitable for this program
3. Company submits a signed and dated .PDF of the license application
4. TTM reviews application, determines if additional information is needed and that it satisfies the requirements of 37 CFR 404;
5. Preliminary Determination (internal review) required
6. Once approved, NCI advertises a “Notice of Intent to Grant an Exclusive License” in the Federal Register with a notice period of 15 days
7. If no relevant objections/comments received during the Notice period, the TTM and company start negotiations

For questions regarding this program, please contact:

Mr. Richard Rodriguez

Associate Director, NCI Technology Transfer Center

Email: Richard.Rodriguez@nih.gov

Phone: 240-276-6661

Q2 2026

